Background {#Sec1}
==========

Diabetes mellitus is one of the strongest risk factors for atherosclerotic diseases \[[@CR1]\]. In Europe and the USA, myocardial infarction is the direct cause of death in 40--50% of patients with diabetes, and the number of patients with diabetes that die as a direct result of ischemic heart disease is reportedly increasing \[[@CR2]\]. In a Finnish study, the rate of incipient myocardial infarction among patients with diabetes was roughly equal to the rate of recurrent myocardial infarction among non-diabetic patients; furthermore, patients with diabetes and prior myocardial infarction demonstrated a greatly increased incidence of myocardial infarction \[[@CR3]\]. Although the application of such results to the Japanese population is not straightforward, existing atherosclerotic vascular lesions and diabetes mellitus are undoubtedly major risk factors for further fatal vascular diseases. Therefore, multifactorial intervention, including control of blood glucose, blood pressure, and lipid levels, is crucial for the prevention of vascular disease \[[@CR4]\].

Dipeptidylpeptidase-4 (DPP-4) inhibitors enhance the action of glucagon-like peptide 1 (GLP-1), the most physiologically important incretin, and they consequently show various actions, such as the stimulation of glucose-dependent insulin secretion, inhibition of glucagon secretion, inhibition of gastric emptying, and appetite regulation \[[@CR5]\]. DPP-4 inhibitors have become standard drugs to improve hemoglobin A1c (HbA1c) levels in patients with diabetes, though improvement of cardiovascular outcomes by adding DPP-4 inhibitors to usual care in diabetic patients with established cardiovascular diseases has not yet been shown \[[@CR6]--[@CR8]\]. Anagliptin is unique among the DPP-4 inhibitors because it was reported to reduce low-density lipoprotein cholesterol (LDL-C) by 9.5 mg/dL over 12 weeks \[[@CR9]\] in phase III trials regardless of the use of statins. This effect of anagliptin may not be a "class effect" of DPP-4 inhibitors, because there has been experimental evidence to suggest that anagliptin inhibits the absorption of cholesterol in the small intestine and cholesterol synthesis in the liver, which presumably are involved in the LDL-C-mediated reduction by anagliptin \[[@CR10]\].

This LDL-C-lowering effect of anagliptin is particularly relevant to diabetic patients with high cardiovascular risk, but such patients are likely to be excluded from clinical trials for regulatory approval. The aim of the present study is, therefore, to investigate the comparative effects of anagliptin and sitagliptin, which was most frequently prescribed in Japan, on LDL-C in patients with type 2 diabetes with dyslipidemia and atherosclerotic vascular lesions.

Methods {#Sec2}
=======

Trial Design {#Sec3}
------------

This is a multicenter, randomized, open-label, parallel-group trial to determine the effectiveness of anagliptin versus sitagliptin on reduction in LDL-C in patients with type 2 diabetes and existing atherosclerotic vascular lesions. Patients with type 2 diabetes and existing atherosclerotic vascular lesions under treatment of statin therapy are included. The eligibility criteria are shown in Table [1](#Tab1){ref-type="table"}.Table 1Patient eligibility criteriaInclusion criteriaPatients who fulfilled all of the following criteria were included1High-risk (\*) patients with type 2 diabetes who are undergoing diet therapy/exercise therapy or are using other hypoglycemic agents in conjunction with diet therapy/exercise therapy2Patients who have been using statins for ≥8 weeks3Patients with LDL-C ≥ 100 mg/gL in ≥ 1 of their previous three measurements after the use of statins4Patients with HbA1c ≥ 6.0% and \< 10.5% (if the investigational drug is added on, HbA1c ≥ 7.0% and \< 10.5%)5Patients aged ≥ 20 years at the time of consent6Patients who provide written consent to participate in the trial of their own free will based on a sufficient understanding of the trial following an adequate explanationExclusion criteriaPatients who met any of the following criteria were excluded1Patients with type 1 diabetes2Patients with TG ≥ 400 mg/dL in a past fasting blood sample3Women who are pregnant, potentially pregnant, or lactating4Patients with severe infections, who are scheduled to undergo/have just undergone surgery, or who have serious trauma5Patients with a serum creatinine level ≥ 2.4 mg/dL for men or ≥ 2.0 mg/dL for women6Patients using GLP-1 receptor agonists7Patients considered ineligible for any other reason by a study investigator\* High-riskDefined as the fulfillment of any one of the following criteria1Stenotic lesions or plaques of ≥ 25% of the arterial diameter in past coronary angiography or CT2Coronary artery calcification in past coronary CT3Past history of acute coronary syndrome4Past history of PCI or CABG5Past history of stroke (ischemic cerebral infarction or cerebral hemorrhage)6Past history of TIA7Past history of peripheral artery disease (including aortic lesions)8Past ankle-brachial index ≤ 0.99Presence of carotid artery plaque (including max IMT ≥ 1.1 mm) in past carotid duplexCABG: coronary artery bypass surgery; CT: computed tomography; GLP-1: glucagon-like peptide-1; HbA1c: hemoglobin A1c; IMT: intima-media thickness; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride; PCI: percutaneous coronary intervention; TIA: transient ischemic attack

Registration, randomization, and data collection are performed using an electronic data capture (EDC) system. Randomization is performed centrally through the EDC system with a stochastic minimization algorithm to balance treatment assignment within and across hospitals, HbA1c (≥ 8.0%, \< 8.0%, use of DPP-4 inhibitors prior to trial registration, sex, body mass index (BMI) (≥ 25 kg/m^2^, \< 25 kg/m^2^), and LDL-C (≥ 130 mg/dL, \< 130 mg/dL).

Trial Oversight {#Sec4}
---------------

The principal investigator, co-principal investigator, and members of the steering committee designed and conducted this study in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan (Table [2](#Tab2){ref-type="table"}). Protocol and consent forms were approved by the institutional review boards at the University of the Ryukyus (No. 731) and each participating center (Table [3](#Tab3){ref-type="table"}) to which important protocol modification and safety information including serious adverse events in this trial are reported. All patients or their legally authorized representatives provide written, informed consent before randomization with investigators. All centers are regularly monitored by steering committee representatives, and the trial is monitored by an independent data and safety monitoring board (Table [2](#Tab2){ref-type="table"}). Auditing this trial is conducted by the audit department of the University of the Ryukyus independently. This trial was registered at [Clinicaltrials.gov](http://clinicaltrials.gov) (NCT02330406).Table 2Study oversightRole of studyNameInstitutionPrincipal investigator\
Steering CommitteeShinichiro Ueda, MD, PhDDepartment of Pharmacology and Therapeutics, University of the RyukyusCo-principal investigator\
Steering CommitteeTakeshi Morimoto, MD, PhD, MPHDepartment of Clinical Epidemiology, Hyogo College of MedicineSteering CommitteeOsamu Arasaki, MDDepartment of Cardiology, Tomishiro Central HospitalSteering CommitteeKoichi Node, MD, PhDDepartment of Cardiovascular Medicine, Saga UniversitySteering CommitteeMichio Shimabukuro, MD, PhDDepartment of Diabetes, Endocrinology and Metabolism, Fukushima Medical UniversitySteering CommitteeTakashi Nomiyama, MD, PhDDepartment of Endocrinology and Diabetes Mellitus, Fukuoka university,Event Adjudication CommitteeAkihiro Tokushige, MD, PhDDepartment of Pharmacology and Therapeutics, University of the RyukyusEvent Adjudication CommitteeMasahiro Natsuaki, MD, PhDDepartment of Cardiovascular Medicine, Saga UniversityEvent Adjudication CommitteeTomohiro Asahi, MD, PhDDepartment of Cardiology, Naha City HospitalData Safety Monitoring BoardKeijiro Saku, MD, PhDGeneral Medical Research Center, Fukuoka UniversityData Safety Monitoring BoardTetsunori Saikawa, MD, PhDOkubo HospitalData Safety Monitoring BoardKohei Kaku, MD, PhDDepartment of General Internal Medicine 1, Kawasaki Medical SchoolStudy statisticianMio Sakuma, MD, PhD, MPHInstitute for Clinical EffectivenessStudy statisticianTakeshi Morimoto, MD, PhD, MPHDepartment of Clinical Epidemiology, Hyogo College of MedicineStudy secretariat--Department of Pharmacology and Therapeutics, University of the RyukyusProject management--Institute for Clinical EffectivenessData management--Institute for Clinical EffectivenessStudy advisorHisao Ogawa, MD, PhDNational Cerebral and Cardiovascular CenterTable 3Participating centers and investigatorsCenterInvestigatorsHokko Memorial ClinicIchiro Sakuma, MD, PhDTomishiro Central HospitalOsamu Arasaki, MDSunagawa Medical ClinicHiroshi Sunagawa, MDImari Arita Kyoritsu HospitalKazuo Matsunaga, MD, PhDOohama Daiichi HospitalRyu Takahashi, MD, PhDChibana ClinicIsao Shiroma, MDNorthern Okinawa Cardiovascular CenterKinya Ashida, MDBaba Memorial HospitalHajime Yamashita, MD, PhDJR Hiroshima HospitalHiroki Teragawa, MD, PhDKusatsu General HospitalAtsuyuki Wada, MD, PhDShonan HospitalKen Nakachi, MD, PhDFukuoka University HospitalTakashi Nomiyama, MD, PhDSaiseikai Fukuoka General HospitalToru Kubota, MD, PhDUrasoe General HospitalHiroki Uehara, MDNaha City HospitalTomohiro Asahi, MD, PhDKokura Memorial HospitalTakashi Morinaga, MDTokushima University HospitalMasataka Sata, MD, PhD

Trial Intervention {#Sec5}
------------------

Patients randomly receive anagliptin or sitagliptin at a ratio of 1:1 (Fig. [1](#Fig1){ref-type="fig"}). Treatment assignment is not concealed from participants or treating physicians. Patients in the anagliptin group are given anagliptin 100 mg orally twice per day for 52 weeks. If the effects are insufficient, the dose can be increased to 200 mg orally twice per day. Patients in the sitagliptin group are given sitagliptin 50 mg orally once per day for 52 weeks. If the effects are insufficient, the dose can be increased to 100 mg per day. If the patients are using anti-diabetic drugs other than DPP-4 inhibitors at the start of the trial, the study drug is administered concomitantly, and such anti-diabetic drugs are not to be replaced.Fig. 1Study design. After the statin administration period and informed consent is obtained, eligible patients are randomly allocated to the anagliptin group who receive twice a day anagliptin at 200 mg per day and to the sitagliptin group who receive once a day sitagliptin at 50 mg per day for 52 weeks, the study drug treatment period

During the trial period, hypoglycemic agents and anti-dyslipidemia drugs (statins, ezetimibe, anion exchange resins, fibrates, and eicosapentaenoic acid (EPA)) are not to be added, and their dosages are not to be changed. A change in dose of insulin is not considered a change in hypoglycemic agents. Other therapy is determined by the physician in charge.

Changes in the medication use as well as other drugs with possible effects on outcome are prohibited. Our clinical research coordinators regularly monitor participants and their physicians about adherence to the study medication/dose at every visit. If cross-over is found, the patients should be dropped out as per protocol.

Measurements {#Sec6}
------------

Through clinical research coordinators or physicians in charge, information on patients is obtained. Clinical characteristics include age, sex, height, waist circumference, body weight, blood pressure, heart rate, past medical history, smoking status, alcohol consumption, drug allergies, and use of concomitant drugs. Blood pressure, heart rate, and compliance with study drug are monitored at 12, 24, 36, and 52 weeks. Height, waist circumference, and body weight were also measured at 52 weeks.

Blood glucose level, red blood cell count, white blood cell count, hemoglobin, hematocrit, platelet count, AST, ALT, γGTP, CK, BUN, and creatinine are measured locally at baseline, 12, 24, 36, and 52 weeks, and LDL-C, HbA1c, total cholesterol (TC), HDL-C, triglycerides (TG), apolipoprotein A1 (Apo-A1), apolipoprotein B (ApoB), apolipoprotein E (ApoE), glycoalbumin, insulin, 1,5-anhydro-D-glucitol (1,5-AG), and C-peptide are measured at the same time periods and analyzed at the core laboratory (SRL Inc., Tokyo, Japan). Small dense LDL, apolipoprotein B48 (ApoB48), high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), campesterol, sitosterols, lathosterol, and high-molecular-weight adiponectin are measured at baseline and at 52 weeks and analyzed at the same core laboratory. Urine albumin and urine creatinine are also measured at baseline and 52 weeks and analyzed at the same core laboratory. Blood samples are obtained at fasting or at least 4 h after a meal. Follow-up is done at the hospital outpatient clinic or referring clinics.

Other substudies such as changes in the measurement of intima media thickness (IMT), detailed lipoprotein profiling, and fractions of fatty acids are included in the protocol. Substudies that are unplanned at this point should be conducted according to the decision of the Steering Committee. Additional serum samples for this purpose are stored.

Endpoints {#Sec7}
---------

The primary endpoint is the change in LDL-C. LDL-C is calculated based on the Friedewald (F) equation. An important secondary endpoint is the change in HbA1c.

Secondary endpoints are changes in the following measurements: fasting blood glucose, fasting insulin, 1,5-AG, C-peptide, TC, TG, HDL-C, non-HDL-C, ApoA1, ApoB, ApoE, ApoB48, small dense LDL, hsCRP, IL-6, campesterol, sitosterols, lathosterol, high-molecular-weight adiponectin, estimated glomerular filtration rate (eGFR), and the urine albumin/creatinine ratio. Secondary endpoints also include progression, lack of change, or remission of microalbuminuria and macroalbuminuria.

Safety outcomes are death and any adverse events systematically reported for 52 weeks, including hypoglycemia, pancreatitis, pancreatic cancer, ileus, and cardiovascular and cerebrovascular events. Safety outcomes are defined in the protocol. Symptoms requiring hospital admission are included, according to the Japanese Ethical Guidelines.

Data Management {#Sec8}
---------------

The details of data management including data entry, coding, security, and storage, including any related processes to promote data quality, are described in the full protocol and more in the standard operation procedures issued by the data center (Institute of Clinical Effectiveness).

Sample Size and Statistical Analysis {#Sec9}
------------------------------------

The present trial seeks to confirm that the anagliptin group is significantly superior to the sitagliptin group in terms of the primary endpoint of change in LDL-C after 52 weeks of treatment. Thus, the null hypothesis is that both anagliptin and sitagliptin groups demonstrate equal changes in LDL-C levels, while the alternative hypothesis is that the sitagliptin and anagliptin groups demonstrate different changes in LDL-C.

It was assumed that reductions in LDL-C after 52 weeks would be similar to a previous report that showed that anagliptin provided an LDL-C decrease of 9.5 mg/dL \[[@CR9]\], whereas sitagliptin provided a decrease of 0.97 mg/dL \[[@CR11]\], with standard deviation (SD) of 21.6 mg/dL for both treatments. With a two-sided alpha of 0.05 and power of 0.8, the sample size was calculated as 102 for each group. Considering a dropout rate of 30%, 300 was set as the total sample size.

This trial was also designed to confirm that the anagliptin group is non-inferior to the sitagliptin group in terms of the important secondary endpoint of the change in HbA1c. The non-inferiority margin of HbA1c was set to 0.3%, which is conventionally used for HbA1c. The null hypothesis is that the 97.5% upper one-sided confidence limit for \[change in HbA1c in sitagliptin group − change in HbA1c in anagliptin group\] ≥ 0.3, and the alternative hypothesis is that the 97.5% upper one-sided confidence limit for \[change in HbA1c in sitagliptin group − change in HbA1c in anagliptin group\] \< 0.3.

A total sample size of 300 provides a power of 0.8 for HbA1c on the assumption that the SD for HbA1c in the anagliptin group based on a previous clinical trial is 0.91, and the non-inferiority margin is 0.3 with a one-sided alpha of 0.025.

The statistical analysis plan (SAP) will be specified before data analysis. The full analysis set (FAS) includes patients who received allocated treatment and provided assessable outcome data. The safety analysis set (SAS) includes patients who received allocated treatment at least once. The per protocol set (PPS) includes patients who received allocated treatment and for whom planned outcome data as per the protocol are available. The FAS is used for the primary endpoint, and the FAS and PPS are used for the important secondary and other secondary endpoints. The SAS is used for safety outcomes. Categorical variables are expressed as frequencies with percentages, and continuous variables are expressed as means with SDs or medians with interquartile ranges (IQRs). All analyses are conducted under the intention-to-treat principle.

Repeated ANOVA with mixed effect models for repeated measures (MMRM) will be developed to compare the anagliptin and sitagliptin groups in terms of change in LDL-C. In this model, treatment allocation and time are treated as fixed effects and include five variables used in balancing factors at randomization as covariates. The same model without covariates of stratification variables will also be developed for sensitivity analyses. The non-inferiority of the anagliptin group to the sitagliptin group in terms of HbA1c levels will be examined with a non-inferiority margin of 0.3%.

For the changes in other endpoints, a one-sample *t* test is used for comparisons of the baseline and follow-up values within the group, and two-sample *t* tests are used for comparisons between groups. The last observation carried forward (LOCF) method is used for missing values.

The number and frequency of categorical safety outcomes will be presented and compared between groups by the chi-squared test or Fisher's exact test. The means are presented with SDs or medians with IQRs for laboratory parameters, and a one-sample *t* test is used for comparisons of the baseline and follow-up values within the group, with two-sample *t* tests used for comparisons between groups. The LOCF method is used for missing values.

Subgroup analyses for the primary and important secondary endpoints will be determined before fixing the SAP. The following pre-specified factors are used for subgroup analyses for the primary and important secondary endpoints: HbA1c (≥ 8.0%, \< 8.0%), use of DPP-4 inhibitors prior to trial registration, sex, BMI (≥ 25 kg/m^2^, \< 25 kg/m^2^), LDL-C (≥ 130 mg/dL, \< 130 mg/dL), age (≥ 65 years, \< 65 years), and the presence of treatment for existing ischemic heart disease before enrollment (PCI or CABG). The statistical significance of possible treatment effect heterogeneity between subgroups is assessed with interaction terms in repeated ANOVA. Other exploratory analyses are conducted based on the consensus of the Steering Committee. Because of the exploratory nature of these analyses for other than the primary endpoint, no correction for multiplicity is made.

All statistical analyses are performed by a study statistician (Morimoto T) and members of the data center (Institute for Clinical Effectiveness) with the use of JMP 13.1 (SAS Institute Inc., Cary, NC) and SAS 9.4 (SAS Institute Inc., Cary, NC) based on the SAP. All *P* values are two-sided, and *P* \< 0.05 is considered significant other than for the non-inferiority test for HbA1c, where a one-sided *P* \< 0.025 is considered significant. For baseline data, missing data are not imputed, and data with missing data are analyzed as they are. Because of the short enrollment and follow-up periods and the estimated low risk of adverse events, no interim analyses are planned.

Discussion {#Sec10}
==========

This pragmatic, randomized, controlled trial was designed to investigate the comparative effects of two DPP-4 inhibitors, anagliptin and sitagliptin, on plasma levels of LDL-C in type 2 diabetic patients with a high risk for cardiovascular diseases. The lipid-lowering effect of anagliptin was first demonstrated in a phase III trial comparing anagliptin to placebo as a single agent or with concurrent anti-diabetic treatment, such as alpha-glucosidase inhibitors, biguanide, sulfonylurea, or thiazolidine in type 2 diabetic patients for 12 weeks \[[@CR9]\]. Anagliptin significantly lowered LDL-C by 5.4 mg/dL and, though it was a before and after comparison, further reduction of LDL-C levels by 9.7 mg/dL compared to those at baseline was observed during the additional observation period extended to 52 weeks. In terms of effects of sitagliptin on lipid metabolism, a similar extended phase III trial showed no significant reduction of LDL-C \[[@CR11]\]. Furthermore, a recent meta-analysis including 11 randomized controlled trials showed that sitagliptin alone or in combination with other drugs significantly improved levels of serum TG and HDL-C but had no effects on LDL-C levels with substantial heterogeneities \[[@CR12]\]. Although these data suggest that LDL-C-lowering effects of anagliptin seem specific among DPP-4 inhibitors, we should, however, interpret them with great caution because measurement of lipid was not the primary end point in most studies and therefore not well standardized among studies. In addition, there has been no direct comparison between anagliptin and other DPP-4 inhibitors. Possible beneficial effects of anagliptin on lipid metabolism, therefore, should also be demonstrated in a pragmatic trial with a longer observation period that compares it to other DPP-4 inhibitor regarding LDL-C as the primary end point and enrolls more relevant patients, i.e., patients with a high cardiovascular risk with insufficient lipid-lowering despite use of statins. From these points of view, this trial was designed to enroll type 2 diabetic patients with at least one atherosclerotic vascular lesion and LDL-C levels above 100 mg/dL on statin treatment, with an observation period of 52 weeks after randomization. Given that DPP-4 inhibitors are the most frequently prescribed anti-diabetic drugs in Japan, comparing anagliptin to sitagliptin as an active control rather than placebo is more realistic and relevant to clinical practice.

Conclusions {#Sec11}
===========

From the points of view discussed above, a pragmatic, unblended, randomized, controlled trial comparing the effects of anagliptin and sitagliptin on plasma LDL-C levels in type 2 diabetic patients with at least one atherosclerotic vascular lesion and insufficient LDL-C lowering despite the use of statins was designed.
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